
November 25th 2020, HollandBIO and Oncode are joining forces to explore what is new in the field of targeted cancer treatments. We are slowly moving away from the ‘one biomarker: one drug’ scenario, which has characterised the first decades of targeted cancer drug development, toward a more integrated approach with multiple biomarkers and drugs.
This ‘new paradigm’ will likely pave the way for the introduction of multiplexing strategies in the clinic using companion diagnostics and patient stratification methodologies. We will cover the frontiering developments from early stage to and clinical studies, clinically validated diagnostics, biomarkers, genomics, and other molecular approaches that are now an indispensable part of 21st century’s cancer treatment.
If you are eager to learn from and connect with top-notch academics, clinicians and entrepreneurs in targeted oncology, mark November 25th in your agenda and sign up below.
Speakers & Programme
Moderator
Annemiek Verkamman – HollandBIO
Session 1
Emile Voest – NKI-AVL
Edwin Cuppen – UMC Utrecht, HMF
Jeroen de Ridder – UMC Utrecht, Cyclomics
Session 2
Caroline van der Meijden – Agendia
Jos Joore – Mimetas
Jeske Timmermans – Roche
Maroeska Rovers – Health Innovation – Netherlands
Practical informaton
Date: November 25th 2020
Time:
- Session 1 - 13.00-14.45hr
- Digital networking - 14:45-15:30hr
- Session 2 - 15.30-17.30hr
- Digital networking - 17:30hr
Venue: Live stream at your home office
Registration
Please register here. Later on, you will receive a registration link to the Hopin platform for the live stream and digital networking.
Sourfce: HollandBIO